A Gene, A Breakthrough, A Challenge: Lessons From the History of Spinal Muscular Atrophy

Area of Science:

• Genetics
• Neurology
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder.
• The identification of the Survival Motor Neuron 1 (SMN1) gene in 1995 and the SMN2 gene was a pivotal moment in SMA research.
• SMA was first described approximately a century ago.

Purpose of the Study:

• To highlight the scientific breakthroughs in understanding SMA genetics.
• To discuss the development and approval of disease-modifying drugs for SMA.
• To address the challenges associated with new SMA treatments, including supportive care and drug accessibility.

Main Methods:

• Review of historical scientific discoveries related to SMA.
• Analysis of the impact of gene identification on drug development.
• Examination of current challenges in SMA treatment access.

Main Results:

• The discovery of SMN1 and SMN2 genes led to three FDA- and EMA-approved disease-modifying drugs.
• These drugs have shown efficacy in improving motor function in children with SMA.
• New challenges include the need for intensive supportive care and high drug costs.

Conclusions:

• Scientific advancements have transformed SMA treatment possibilities.
• There is an urgent need for a global strategy to ensure equitable distribution of SMA therapies.
• Balancing therapeutic benefits with the practicalities of care and cost is essential for the SMA community.